000 | 02044ngm a2200349 a 4500 | ||
---|---|---|---|
001 | HST2296_1_2 | ||
003 | UkLoHST | ||
006 | m c | ||
007 | cr|cna|||a|||| | ||
007 | vz|czazum | ||
008 | 080121s2009 enk|||||||||||s|||v|eng d | ||
028 | 5 | 0 |
_a2296 _bHenry Stewart Talks |
035 | _a(UkLoHST)1353 | ||
035 | _a(UkLU-K)001155609 | ||
040 |
_aUkLU-K _beng _cUkLU-K |
||
100 | 1 |
_aCavagnaro, Joy A. _4spk |
|
245 | 1 | 0 |
_aPreclinical safety evaluation of biopharmaceuticals _h[electronic resource] : _bscience-based approach to facilitating clinical trials / _cJoy Cavagnaro. |
246 | 1 |
_iTitle from publisher's web site. _aPreclinical safety evaluation of biopharmaceuticals : _bscience-based approach of facilitating clinical trials |
|
260 |
_aLondon : _bHenry Stewart Talks, _c2009. |
||
300 |
_a1 online resource (1 streaming video file (46 min.) : _bcolor, sound). |
||
490 | 1 |
_aNon-clinical testing for toxicity of pharmaceuticals : regulatory and practical standards for testing and application, _x2056-452X |
|
500 | _aAnimated audio-visual presentation with synchonized narration. | ||
500 | _aTitle from title frames. | ||
505 | 0 | _aContents: Optimization of the clinical development of biopharmaceuticals over the past two decades has relied upon the careful design and judicious use of animals in preclinical studies -- This is not only to allow for the early initiation of clinical studies but to support an uninterrupted clinical development program -- The approach has been referred to as "case-by-case", an approach which is science-based, question-based, experience-based and targeted based upon product attributes. | |
506 | _aAccess restricted to subscribers. | ||
538 | _aMode of access: World Wide Web. | ||
650 | 2 | _aDrug Toxicity. | |
650 | 2 | _aToxicity Tests. | |
830 | 0 |
_aHenry Stewart talks. _pBiomedical & life sciences collection. _pNon-clinical testing for toxicity of pharmaceuticals. |
|
856 | 4 | 0 | _uhttps://hstalks.com/bs/1353/ |
856 | 4 | 2 |
_uhttps://hstalks.com/bs/p/438/ _3Series |
999 |
_c77718 _d77718 |